BNET Industries

DUSA Pharmaceuticals Inc.

(DUSA) is in the Pharma Industry

Market Cap:$31.1M
Last Fiscal Year Sales:$29.5M
  • Public
  • US
Dow Jones Description

We are a vertically integrated dermatology company that is developing and marketing Levulan ® photodynamic therapy, or PDT, and other products for common skin conditions. Our marketed products include Levulan ® Kerastick ® 20% Topical Solution with PDT, the BLU-U ® brand light source, and ClindaReach ® . Historically, we devoted most of our resources to advancing the development and marketing of our Levulan ® PDT technology platform. In addition to our marketed products, our drug, Levulan ® brand of aminolevulinic acid HCl, or ALA, in combination with light, has been studied in a broad range of medical conditions. When Levulan ® is used and followed with exposure to light to treat a medical condition, it is known as Levulan ® PDT. The Kerastick ® is our proprietary applicator that delivers Levulan ® . The BLU-U ® is our patented light device.

CFO & Vice President, Finance
Richard C. Christopher
Number of Employees 84
Contact Information

25 Upton Dr

Wilmington, Massachusetts 01887

dusapharma.com

1 978 657 6502

NAICS Code Pharmaceutical Preparation Manufacturing: 325412

Recent Events

  • DUSA Pharmaceuticals Reports Third Quarter 2009 Corporate Highlights and Financial Results

    11/06/09 - Financial Announcement - View Story

  • DUSA Pharmaceuticals, Inc.: DUSA Pharmaceuticals Reports First Quarter 2009 Corporate Highlights and Financial Results

    5/12/09 - Financial Announcement - View Story

  • DUSA Pharmaceuticals, Inc.: DUSA Elects Alexander Casdin to Board of Directors

    1/29/09 - Board Member - Entering - View Story

  • DUSA Pharmaceuticals Reports Second Quarter 2008 Corporate

    8/08/08 - Financial Announcement - View Story

  • DUSA Pharmaceuticals Reports First Quarter 2008 Corporate Highlights and Financial Results

    5/07/08 - Financial Announcement - View Story

  • Dusa Pharma Q4 Net Loss Narrows [DUSA]

    3/04/08 - Financial Announcement - View Story

  • OTCPicks.com: OTCPicks.com Daily Market Movers Digest Midday Report for November 9th VSUR, UVSE, DUSA, TNRI

    11/09/07 - Financial Announcement - View Story

  • www.streetinvesting.com: USA Pharmaceuticals Inc. Against Current Markets

    6/15/07 - Mgmt. Change - Entering - View Story

News & Analysis

dusa pharmaceuticals inc. and finance - All News and Analysis

Decision Makers

Name (plus bio) Position
Richard C. Christopher CFO & Vice President, Finance
William O'Dell Executive Vice President, Sales & Marketing
David Page Associate Vice President, Sales
Michael J. Todisco Vice President, Controller
Paul A. Sowydra Vice President, Marketing
Paul Sowyrda Vice President, Prod Marketing, Sales
Scott Lundahl Vice President, Regulatory Affairs & Intellectual Property
Shari Lovell Director, Shareholder Services
Ed Sinamark Manager, IT
Magnus Moliteus Consultant
Nanette W. Mantell Secretary

Board of Directors

Name (plus bio) Position
Stuart Marcus Board of Directors
Mark Carota Board of Directors
Jay Haft Board of Directors
D. Geoffrey Shulman Board of Directors
David M. Bartash Board of Directors
John H. Abeles Board of Directors
Richard C. Lufkin Board of Directors
Robert F Doman Board of Directors

Organization Position Status
DUSA Pharmaceuticals, Inc. CFO & Vice President, Finance Current

Organization Position Status
DUSA Pharmaceuticals, Inc. Vice President, Scientific Affairs and Chief Medical Officer Current
DUSA Pharmaceuticals, Inc. Board of Directors Current

Organization Position Status
DUSA Pharmaceuticals, Inc. Executive Vice President, Sales & Marketing Current

Organization Position Status
DUSA Pharmaceuticals, Inc. Associate Vice President, Sales Current

Organization Position Status
DUSA Pharmaceuticals, Inc. Vice President, Operations Current
DUSA Pharmaceuticals, Inc. Board of Directors Current

Organization Position Status
DUSA Pharmaceuticals, Inc. Vice President, Controller Current

Organization Position Status
DUSA Pharmaceuticals, Inc. Vice President, Marketing Current

Organization Position Status
DUSA Pharmaceuticals, Inc. Vice President, Prod Marketing, Sales Current

Organization Position Status
DUSA Pharmaceuticals, Inc. Vice President, Regulatory Affairs & Intellectual Property Current
DUSA Pharmaceuticals, Inc. Board of Directors Current

Organization Position Status
DUSA Pharmaceuticals, Inc. Director, Shareholder Services Current
DUSA Pharmaceuticals, Inc. Director, Shareholder Services Former

Organization Position Status
DUSA Pharmaceuticals, Inc. Manager, IT Current

Organization Position Status
Columbus Nova Partner Current
DUSA Pharmaceuticals, Inc. ViceChairman Current
Reable Therapeutics, Inc. Chairman Current
CompuCom Chairman Current
Dcap Group, Inc. Director Current
Concert Association of Florida, Inc Board Member Current
Dusa Board of Directors Current
DUSA Pharmaceuticals, Inc. Board of Directors Current
Miami City Ballet Inc. Treasurer Current
The Haft, Incorporated Senior Corporate Partner Former
Rosoff Senior Corporate Partner Former
Oryx Technology Corp Former
Yale University B.A. Former
Yale College B.S. Former
Yale University Degree Former
Columbus Nova Member Former

Magnus Moliteus is a consultant to the healthcare industry and Chairman of COM Consulting Inc., a privately held firm, which enhances Swedish-American relations particularly between health care companies. From 1995 to 2001, when he became a full-time consultant, Mr. Moliteus served as Executive Director of Invest in Sweden Agency, U.S., a Swedish government agency. From 1977 to 1990, he was Chief Executive Officer of Pharmacia, Inc. (now owned by Pfizer, Inc.)

Organization Position Status
DUSA Pharmaceuticals, Inc. Consultant Current
Dusa Consultant Current
Dusa Board of Directors Current
DUSA Pharmaceuticals, Inc. Board of Directors Current
Pharmacia Corporation Chief Executive Officer Former
Invest.Com Executive Director Former

Organization Position Status
DUSA Pharmaceuticals, Inc. Secretary Current
DUSA Pharmaceuticals, Inc. Secretary Current

Organization Position Status
DUSA Pharmaceuticals, Inc. Board of Directors Current
DUSA Pharmaceuticals, Inc. Chairman & CEO Former
Draxis Health, Inc. President Former
Draxis Health, Inc. Director Former

David M. Bartash, is the President and founder of Bartash and Company, a consulting company which, since 1990, has been providing consulting services for the healthcare industry, including research for the healthcare investment community and support services for venture start-ups.

Organization Position Status
DUSA Pharmaceuticals, Inc. Board of Directors Current

Dr. Abeles is the founder of MedVest, Inc., which has provided consulting services to health care and high technology companies since 1980 and where he has served as President since 1982. Since 1998, he has served as Chairman of UniMedica Inc., a web-enabled Medical School education consulting and publishing firm. Since 1992, Dr. Abeles has been the general partner of Northlea Partners, Ltd., an investment and venture capital firm. Since 1998, he has also served as Assistant Professor, Clinical Pharmacology and Therapeutics at the International University of Health Sciences. Dr. Abeles has been a member of the Boards of Directors of the following companies since the date noted: CombiMatrix Molecular Diagnostics, Inc. (1996), DUSA Pharmaceuticals, Inc. (1995), I-Flow Corporation (1987), and Oryx Technology (1989). Since 1997, Dr. Abeles has served as a Director of Higuchi Bio-Science Institute, University of Kansas, and since 2001 has served as Director of College of Chemistry Advisory Board, University of California Dr. Abeles joined our Board of Directors in December 2006, and has served on our CombiMatrix Scientific Advisory Board since June 2006.

Organization Position Status
MedVest, Inc. President Current
MedVest, Inc. Founder Current
Dusa Board of Directors Current
New York Academy of Sciences Board of Directors Current
DUSA Pharmaceuticals, Inc. Board of Directors Current
Prescient Medical, Inc Board of Directors Current
Cytocore, Inc. Board of Directors Current
Combimatrix Corporation Director Current
Cytocore Inc Board of Directors Current
Etubics Corporation Board of Directors Current
I-Flow Corporation Board of Directors Current
New York Academy of Sciences Member Current
Kidder, Peabody & Co. Healthcare Analyst Former
Pfizer Inc. Clinical Research Medical Executive Former
Sterling Drug Clinical Research Medical Executive Former
University of Birmingham Degree In Pharmacology Former
Oryx Technology Corp member Former

Richard C. Lufkin is the principal of Enterprise Development Associates, through which he provides consulting and venture support services to early stage technology-based companies. He is a founder of several firms, principally in the pharmaceutical, biotechnology, and medical device fields.

Organization Position Status
DUSA Pharmaceuticals, Inc. Board of Directors Current
Linguagen Corp Chief Financial Officer Former

Robert F. Doman, has been employed by the Company as President and Chief Operating Officer since January 2005. From 2000 until 2004, Mr. Doman served as President of Leach Technology Group, the medical device division of Leach Holding Corporation. From 1999 to 2000, he was President, Device Products Development, of West Pharmaceutical Services, a manufacturer of systems and device components for parentally administered medicines and drugs. Prior to joining West Pharmaceutical Services, he worked for the Convatec division of Bristol-Myers Squibb from 1991 to 1999 in positions that included: Vice President, Worldwide Marketing and Business Development; Vice President and General Manager, U.S. Wound and Skin Care; and Vice President, U.S. Operations.

Organization Position Status
Dusa President and Chief Executive Officer Current
Dusa Board of Directors Current
DUSA Pharmaceuticals, Inc. Board of Directors Current
West Pharmaceutical Services, Inc. President Former
advertisement
     DUSA $1.75 -0.02 (-0.94% )
Intraday | 3 Month | 6 Month | 1 Year
Average Volume 66,877
Shares Outstanding 24.11M
Market Cap 42.2M
Year High 1.87
Year Low 0.88
Earnings Per Share -0.10
P/E Ratio -17.50
Dividend N/A
Yield N/A
IndustryTop Rated

Brought to you by CBS MoneyWatch.com

advertisement